Black Diamond Therapeutics, Inc. (BDTX) Stock Forecast
BDTX analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.50 / 5 from 8 analysts
- Price target
- $10.00 average of analyst targets
- Upside to target
- +481.4% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $-0.03
- 52-week range
- $1.61 – $4.87
BDTX analyst ratings
8 analystsNumber of analysts at each rating.
BDTX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
BDTX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.06 | −$0.24 | $0.62 | −$0.15 | +63.3% | 6 |
| Current fiscal year (2026) | −$0.57 | −$0.75 | −$0.01 | $0.52 | −209.8% | 6 |
| Next fiscal year (2027) | −$1.00 | −$1.75 | −$0.52 | −$0.57 | −76.5% | 6 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
BDTX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $6.2M | $0 | $50.0M | 0.0% | 8 |
| Current fiscal year (2026) | $6.2M | $0 | $50.0M | −91.1% | 8 |
| Next fiscal year (2027) | $0 | $0 | $0 | −100.0% | 8 |
BDTX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
BDTX revenue: reported and forecast
BDTX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.06 | −$0.06 | −$0.06 | −$0.06 | −$0.06 | 0.0% | 1 up · 0 down |
| Current fiscal year (2026) | −$0.63 | −$0.63 | −$0.63 | −$0.63 | −$0.57 | −10.0% | 1 up · 0 down |
| Next fiscal year (2027) | −$1.09 | −$1.16 | −$1.16 | −$1.16 | −$1.00 | −8.3% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
BDTX earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; BDTX beat in 12 of 12.
What analysts expect from BDTX
8 analysts cover Black Diamond Therapeutics; their consensus rating is strong buy (4.50 on a 1–5 scale, where 5 is a strong buy). The average price target is $10.00, 481.4% above the latest close of $1.72. Analysts expect earnings of −$0.57 per share for 2026, −209.8% from a year earlier. For 2027 the average estimate is −$1.00 per share. Black Diamond Therapeutics beat the EPS estimate in 12 of the last 12 quarters.
Related: BDTX income statement, BDTX key metrics, BDTX chart. See the BDTX stock overview for the latest quote and news.
BDTX forecast FAQ
What is Black Diamond Therapeutics's price target?
The average analyst price target for Black Diamond Therapeutics is $10.00, 481.4% above the latest close of $1.72.
Is Black Diamond Therapeutics a buy, hold or sell?
Of 8 analysts covering Black Diamond Therapeutics, 5 rate it a strong buy, 2 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Black Diamond Therapeutics's EPS forecast?
Analysts forecast −$0.57 per share for 2026 (range −$0.75 to −$0.01); for 2027 the estimate is −$1.00.
What is Black Diamond Therapeutics's revenue forecast?
The average revenue estimate for 2026 is $6.2 million, growth of −91.1%.
When does Black Diamond Therapeutics report earnings?
Black Diamond Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 after the market closes; the EPS estimate is $-0.03.
Does Black Diamond Therapeutics usually beat earnings estimates?
Black Diamond Therapeutics reported EPS at or above the analyst estimate in 12 of the last 12 quarters.